Pharmaceutical Technology on MSN
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo
AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab ...
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...
May 27 (Reuters) - AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended the decision deadline for ...
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive ...
AstraZeneca (AZN) stock is in focus as the FDA delays review of a breast cancer therapy containing its next-gen oral SERD ...
AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu in early-stage HER2-positive breast cancer in both ...
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...
2d
AstraZeneca falls 7% as Q4 net profit declines 23%; here's a trading strategy for the pharma stock
An analyst said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader ...
The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results